Artemisinin drug resistance and monitoring: a narrative review

Artemisinin drug resistance is one of the major reasons for malaria treatment failures in the sub-Saharan African countries where artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria. The occurrence of single nucleotide polymorphisms (SNPs) is found to correlate with antimalarial drug resistance. With artemisinin, the SNPs occurs at the Kelch 13-propeller gene locus on chromosome 13. The artemisinin drug resistance surveillance strategy involves continuous monitoring of Kelch 13-propeller biomarker to detect emergence of mutations which could herald drug resistance in the region. In this narrative review paper, we examined existing literature to bridge the knowledge gap and accentuate the importance of routine surveillance for artemisinin resistance in sub-Saharan Africa. We conducted our search on PubMed database and Google Scholar to identify peer-reviewed articles, reports, and abstracts on artemisinin drug resistance using the following keywords; 'artemisinin drug resistance', 'antimalarial drug resistance', 'artemisinin-based combination therapy', 'Kelch 13-propeller', 'K13- propeller gene', and 'K13 molecular marker'. The review provided pertinent information on artemisinin derivatives, artemisinin-based combination therapy, molecular action of artemisinin, definition of artemisinin resistance, genetic basis of artemisinin drug resistance and discovery of Kelch 13, and the importance of artemisinin resistance surveillance. Molecular surveillance can provide healthcare policy makers a forecast of impending threats to malaria treatment. This is more so when drugs are in combination therapy, for instance, molecular surveillance can give a hint that one drug is failing despite the fact that in combination, it is still apparently clinically effective.

La résistance aux médicaments à base d'artémisinine est l'une des principales raisons des échecs du traitement du paludisme dans les pays d'Afrique subsaharienne où la polythérapie à base d'artémisinine (ACT) est le traitement de première intention du paludisme simple. L'apparition de polymorphismes mononucléotidiques (SNP) est corrélée à la résistance aux médicaments antipaludiques. Avec l'artémisinine, les SNP se produisent au locus du gène Kelch 13- propeller sur le chromosome 13. La stratégie de surveillance de la résistance aux médicaments à base d'artémisinine implique une surveillance continue du biomarqueur Kelch 13-propeller pour détecter l'émergence de mutations qui pourraient annoncer une résistance aux médicaments dans la région. Dans cet article de revue narrative, nous avons examiné la littérature existante pour combler le manque de connaissances et accentuer l'importance de la surveillance de routine de la résistance à l'artémisinine en Afrique subsaharienne. Nous avons effectué notre recherche sur la base de données PubMed et Google Scholar pour identifier des articles, des rapports et des résumés évalués par des pairs sur la résistance aux médicaments à base d'artémisinine en utilisant les mots-clés suivants; «résistance aux médicaments à base d'artémisinine¼, «résistance aux médicaments antipaludiques¼, «thérapie combinée à base d'artémisinine¼, «Kelch 13-propeller¼, «gène K13-propeller¼ et «marqueur moléculaire K13¼. L'examen a fourni des informations pertinentes sur les dérivés de l'artémisinine, la polythérapie à base d'artémisinine, l'action moléculaire de l'artémisinine, la définition de la résistance à l'artémisinine, la base génétique de la résistance aux médicaments à base d'artémisinine et la découverte de Kelch 13, ainsi que l'importance de la surveillance de la résistance à l'artémisinine. La surveillance moléculaire peut fournir aux responsables des politiques de santé une prévision des menaces imminentes pour le traitement du paludisme. C'est d'autant plus vrai lorsque les médicaments sont en thérapie combinée, par exemple, la surveillance moléculaire peut donner un indice qu'un médicament échoue malgré le fait qu'en combinaison, il est toujours apparemment cliniquement efficace.

Outcome of acute urinary tract infections caused by uropathogenic Escherichia coli with phenotypically demonstrable virulence factors

Background: Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) strains is one of the most important community-acquired infections in the world. The presence of virulence factors is closely related with the pathogenesis of UTI. Methods: The present study was conducted on 150 isolates of UPEC obtained from symptomatic and asymptomatic cases of UTIs with significant counts (≥105 CFU/ml) during 1 year. UPEC isolates were studied for hemolysis on 5% sheep blood agar, mannose-sensitive hemagglutination (MSHA), mannose-resistant hemagglutination (MRHA), and biofilm formation by recommended methods. Patients with UTI due to UPEC showing virulence factors were evaluated for the treatment received and the outcome of treatment. These were compared with the outcomes of patients whose culture samples grew UPEC without demonstrable virulence factors. Results: The study showed hemolysin production in 40% of the isolates. Forty percent of the isolates showed the presence of P fimbriae (MRHA) and 60% showed Type 1 fimbriae (MSHA). Biofilm formation capacity of all UPEC isolates was classified into three categories, strong biofilm producers (4%), moderate biofilm producers (88%), and nonbiofilm producers (8%). Patients harboring all three virulence factors showed 76% recovery compared to patients harboring strains with no demonstrable virulence factors, who showed 100% recovery. Conclusion: The present study has shown the production of various virulent factors and developing drug resistance in UPEC. Treatment outcomes of patients harboring strains with no virulence factors seem to be better than the ones which contain multiple virulence factors. UPEC occurs because of multiple virulence factors. Biofilm formation and MRHA are more likely to be seen in catheterized patients. The drug resistance among UPEC is on rise; therefore, the selection of appropriate antibiotics (after antibiotic susceptibility testing) is must for proper treatment of patients and to avoid emergence of drug resistance. Significant number of the UPEC isolates was sensitive to nitrofurantoin, and half of the isolates were sensitive to cotrimoxazole, so treatment is by giving these drugs orally

Enteropathogens in under-five children with diarrhea in health facilities of Debre Berhan Town, North Shoa, Ethiopia

BACKGROUND: Diarrheal disease is a major cause of mortality and morbidity for under-five children in Ethiopia. The purpose of this study was to investigate the behavioral and socioeconomic risk factors, etiology, and drug susceptibility of bacteria isolated from under-five children with acute diarrhea who were treated at Debre Berhan Referral Hospital or Health Center in Ethiopia. METHODS: A health facility based cross-sectional study design was used to investigate enteropathogens from 163 under-five children with acute diarrhea. After obtaining written consent from parents or guardians, data were collected using a standardized questionnaire. Freshly passed stool samples were collected for microbiological tests for bacteria and parasites. The chi-square test was used for assessing the relationships of variables. RESULTS: Enteropathogens were detected among 55.8% (91/163) participants. There was a 46%(75/163) bacterial culture positivity rate and a 9.8%(16/163) prevalence of parasites. The isolated enteropathogens were Escherchia coli, Klebsiella specie, Proteus species, Salmonella species, Shigella species, Enterobacter species, Giardia lamblia, Enteameba histolytica, Ascaris lumbricoides, Trichuris trichiura and Hymnoleps nana. Level of antimicrobial resistance of bacterial isolates ranged from 0 to 87.2%. Poor hand washing and poor cleaning of feeding utensils showed significant association with the presence of enteropathogens. CONCLUSION: Bacterial enteropathogens with drug resistance were observed in this study. Continuous health education and promotion about diarrheal disease for mothers/caretakers and regular surveillance of entropathogenes are recommended to reduce under-five mortality

Adherence to antimalarial drug policy among doctors in Delta State, Nigeria: implications for malaria control

Background: Malaria is a public health problem compounded with a widespread emergence of drug-resistant Plasmodium falciparum which necessitated the formulation of a new antimalarial drug policy (AMP).Objective: This study was designed to assess adherence to the policy among physicians in health facilities in Delta state, Nigeria. Design: Cross-sectional, analytic study. Data were collected with a semi-structured questionnaire.Setting: Two secondary and one tertiary health facilities in Delta State, Nigeria Participants: Physicians selected with a simple random technique from the facilities Main outcome measures: Prescribing pattern of antimalarial drugs and adherence to WHO treatment guideline among doctors. Results: Majority (90.8%) of respondents believed the antimalarial policy (AMP) should be strictly adhered to, although three-fifth (61.0%) of them rated its performance as poor. The level of adherence to the national antimalarial drug policy was high (78.5%) as most doctors prescribed Arthemeter-Lumefantrine, AL for uncomplicated malaria however barely two-fifth (35.4%) adhered to prescribing injectable Artesunate for complicated malaria. AL, (71.9%) was the most prescribed antimalarial drug for uncomplicated malaria The most prescribed antimalarial drugs for complicated malaria was artesunate (40.0%) followed by quinine (27.6%) and artemether (26.7%); although, chloroquine was also prescribed.Conclusion: The level of adherence to AMP among doctors was sub-optimal. Continuous education of doctors on the new AMP is needed to achieve malarial control

Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso

The emergence of HIV-1 drug resistance (HIVDR) is a public health problem that affects women and children. Local data of HIVDR is critical to improving their care and treatment. So, we investigated HIVDR in mothers and infants receiving antiretroviral therapy (ART) at Saint Camille Hospital of Ouagadougou, Burkina Faso. This study included 50 mothers and 50 infants on ART. CD4 and HIV-1 viral load were determined using FACSCount and Abbott m2000rt respectively. HIVDR was determined in patients with virologic failure using ViroSeq HIV-1 Genotyping System kit on the 3130 Genetic Analyzer. The median age was 37.28 years in mothers and 1.58 year in infants. Sequencing of samples showed subtypes CRF02_AG (55.56%), CRF06_cpx (33.33%) and G (11.11%). M184V was the most frequent and was associated with highlevel resistance to 3TC, FTC, and ABC. Other mutations such as T215F/Y, D67N/E, K70R, and K219Q were associated with intermediate resistance to TDF, AZT, and 3TC. No mutation to LPV/r was detected among mothers and infants. The findings of HIVDR in some mothers and infants suggested the change of treatment for these persons

Alerte précoce de la pharmacorésistance du VIH au Togo

Introduction. Dans le cadre de l'ambition globale de mettre fin à l'épidémie du VIH, le Togo a débuté en 2016 la stratégie « Tester et traiter » proposée par l'ONUSIDA pour les cibles telles que les femmes enceintes, couples sérodiscordants, enfants, patients coinfectés TB/VIH, populations clés. Ainsi la stratégie nationale prévoit d'atteindre 90% de couverture de traitement antirétroviral (TARV) à l'horizon 2020. Le passage à grande échelle du TARV peut occasionner une augmentation du risque d'émergence des résistances du VIH aux ARV (RDVIH). La résistance pouvant mettre en échec l'impact de l'accélération en cours du Traitement ARV, nous avons évalué au Togo les indicateurs d'alerte précoce de la pharmacorésistance du VIH (IAP). C'est une stratégie reconnue efficiente dans les pays à ressources limitées pour assurer l'efficacité des protocoles antirétroviraux de première ligne moins dispendieux. Méthodologie. Nous avons en juin 2017 suivant les normes de l'OMS mené une étude rétrospective dans 80 sites de TARV représentatifs des 06 régions sanitaires du pays. Les cinq IAP suivants ont été étudiés : IAP1 : Retrait des médicaments ARV dans les délais ; avec comme seuils : Rouge <80% ; Orange 80­90% ; Vert >90%. IAP2 : Rétention sous TARV après 12 mois d'initiation du traitement avec pour seuils : Rouge <75%; Orange 75­85%; Vert >85%. IAP3 : Ruptures de stocks de médicaments avec comme seuils : Rouge <100%; Vert =100% sans rupture de stock en 2016, IAP4: Pratiques de prescription à l'initiation du traitement ARV avec comme seuils: Rouge <100%; Vert =100% de prescription conformes aux directives nationales. IAP5a : Couverture de réalisation des charges virales avec rendu des résultats avec comme seuils : Rouge < 70%, Vert > 70% des patients ayant une charge virale disponible à 12 mois de TARV. IAP5b: suppression de la charge virale à 12 mois avec pour seuils: Rouge <75%, Orange 75-90%, Vert >90% de suppression de charge virale à 12 mois de TARV, Résultats. Seuls 5468 patients (67%) ont retiré leurs médicaments dans les délais. Cependant 91% (3429/3767) des personnes initiées au TARV sont restées sous traitement douze mois après (IAP 2) mais seulement 5,2% (178/3429) des PVVIH dans le besoin ont eu accès à l'examen de la charge virale, (5a). Seuls 13 sites parmi les 36 ayant un score vert à l'IAP2 avaient atteint l'objectif de suppression de la charge virale (IAP 5b.). Seuls 63 sites sur les 80 ont atteint le seuil de l'IAP et 36/80 enquêtés ont pu atteindre l'objectif de l'IAP2. Conclusion. Nos résultats font craindre un risque d'émergence de la pharmaco-résistance du VIH sur le plan national. Les pratiques de dispensation sont conformes aux directives nationales, la rétention sous TARV à 12 mois est excellente, mais le respect des délais de retrait des médicaments ARV et les ruptures de stocks dans l'approvisionnement des ARV, constituent des facteurs majeurs dans plusieurs sites, pouvant permettre l'émergence de la pharmaco-résistance du VIH au Togo. La couverture de l'examen de la charge virale est très faible et nécessite en urgence d'être étendue

Imatinib theraphy in chronic myeloid leukaemia : review of mechanisms of resistance and therapheutic options in imatinib failure

Chronic myeloid leukaemia is triphasic, clonal malignancy, arising from the haemopoeitic stem cell. It is characterized by the presence of philadelphia chromosome, which result from reciprocal translocation between chromosome 9 and 22. The resulting oncogen- brc-abl has proliferative activity and survival advantage against normal cell and this account for the clinical and laboratory manifestation of this myeloproliferative disorder. Imatinib, a tyrosine kinase inhibitor (TKIs) is currently the first line of treatment, however, one third of patient develope resistance to it, thus necessitating alternative TKIs. Many factors are associated with the development of resistance to imatinib, such as mutation in the brc-abl gene, increase production of the mutant protein and activation of alternatve pathways amongst other causes. The aim of this reveiw is to explore these factors, and also to avaluate current TKIs that are use as alternative in Imatinib resistant cases

Hepatitis B Infection in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy in Lome; Togo: Prevalence and Molecular Consequences

BACKGROUND:No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo; and patients are not routinely tested for HBV infection.OBJECTIVE:To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.METHOD:This cross-sectional study was carried out in Lome; Togo; from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.RESULTS:In total; 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients; 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive; and 115 (98.3%) were on lamivudine. The HBV DNA load was etgt;10 IU/mL in 33/117 patients overall (38%); and in 87.5% of 16 HBeAg-positive patients (petlt;0.0001). In multivariate analysis; factors associated with HBV DNA load etgt;10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).CONCLUSION:The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing

Prevalence of Extended Spectrum beta-Lactamase-Producing Klebsiella Species at the University of Ilorin Teaching Hospital

Background: Persistent blind antibiotic treatment of patients; in resource poor nations like Nigeria; makes the prevalence of antibiotic resistance to increase sporadically. Extended spectrum beta-lactamase (ESBL) production is one of the ways by which bacteria become resistant to antibiotics. For this reason; isolation; identification; sensitivity and screening for possible resistance genes is very important before prescription; if the affected patients must receive qualitative care particularly when their condition is chronic. Materials and Methods: Four hundred suspected isolates of Klebsiella belonging to various species obtained from routine specimens such as swabs; urine; blood; and sputum from May to October 2009 were studied. The identity of all isolates obtained was biochemically analyzed. The isolates were subjected to antibiotic susceptibility testing using modified Kirby-Bauer method and ESBL production was phenotypically determined using double disc synergy test for laboratory detection and reporting of bacteria by CLSI method. Results: Ninety-eight (24.5%) isolates expressed ESBL. Majority of the ESBL producing isolates were from swab specimens 59 (14.75%) followed by blood culture 16 (4.0%); urine 13 (3.25%); and sputum 10 (2.5%). Sensitivity patterns of ESBL producing Klebsiella spp. revealed that all ware resistant to augmentin (AUG); ceftazidime (CAZ); cefotaxime (CTX); cefuroxime (CRO); cefpodoxime (CPD); and none resistant to imipenem (IMP).Conclusion: ESBL producing Klebsiella spp.; were present in University of Ilorin Teaching Hospital. They are resistant to augmentin (AUG); CAZ; CTX; and CPD. Presence of ESBL in any Klebsiella spp. has made cephalosporins which are first line antibiotics usually given non-effective; thereby reducing the treatment options. We; therefore; suggest screening and confirmation for ESBL; in other to prevent treatment failure

Prevalence and Antibiotic Resistance Patterns of Escherichia coli among Hospitalised Patients at Thika District Hospital

Background: Emerging resistance to antimicrobial drugs increases morbidity and mortality by hampering the provision of effective chemotherapy; and makes treatment more costly. The emergence of resistance to antimicrobial agents is a global public health problem; especially in pathogens causing nosocomial infections. Objectives: To determine the carriage of E. coli from wounds and urine in catheterised inpatients at Thika District Hospital (TDH) and to determine antimicrobial resistance patterns to Beta-lactams; aminoglycosides and (fluoro) quinolones. Design: A cross-sectional study. Setting: Thika District Hospital among hospitalised patients. Subjects: A total of 450 specimens were collected and forty two (42) Escherichia coli isolated. Pus swabs were collected from wounds and urine was collected aseptically from the inpatients with catheters. Escherichia coli were identified by culture methods and biochemical tests. Antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion method and interpreted according to Clinical Laboratory Standards Institute recommendations. Results: Susceptibility results in aminoglycosides were; resistance for amikacin; gentamicin and kanamycin was 20; 39 and 51 respectively. Resistance in penicillin was ampicillin 85 and piperacillin 83 . Resistance for sulfamethoxazole was 83; tetracycline 66 ; nalidixic acid 44; nalidixic acid 44 and chloramphenicol 39and chloramphenicol 39. In amoxicillin/clavulanic acid; resistance was 68 . Cephalosporins' resistance was ceftazidime 22 ; cefotaxime 56 . Resistance for imipenem and tazobactam was 7 and 12 respectively. Conclusion: Due to observations on resistance to antimicrobial agents commonly used in Thika District Hospital; this shows that there is need to revise antimicrobial policy in this region in the treatment of E. coli infections

Nonadherence to First-Line Antiretroviral Therapy among Human Immunodeficiency Virus-1 Infected Children at the Jos University Teaching Hospital; Jos; Nigeria

Background: Nonadherence to antiretroviral therapy (ART) may encourage the development of resistance to antiretroviral drugs (ARVs). Poor adherence is known to be associated with ART failure which could compromise the benefits of ART in children. Therefore; it is important to identify the reasons why children on ART may fail to take their ARVs. In this study; we described the characteristics of human immunodeficiency virus-1 (HIV-1) infected children with ART nonadherence as well as the reasons for their nonadherence. Methodology: A retrospective cohort study in which data on 580 HIV-1 infected children enrolled on ART between February 2006 and December 2010 at the pediatric HIV clinic of the Jos University Teaching Hospital; Jos; was analyzed. Subjects were aged 2 months to 15 years. Information on adherence was obtained by child or caregiver self-report. They also had repeated adherence counseling during each clinic follow-up visit and were taught the use of alarm clocks daily for reminding them of when the next ARV dose will be due. Results: There were 30 (5.2) children with non-adherence to ART. Among children with nonadherence; majority were: Children aged 1-10 years (76.7); males (53.3) and did not know their diagnosis of HIV (90.9). The odds of nonadherence was two times higher among children who failed first-line ART compared with those who did not (odds ratio [95 confidence interval]; 2.28 [1.03-5.02]; P = 0.04). The most common reason for nonadherence was: Forgot to take medications (46.7). Conclusion: The low rate of nonadherence to ART in this study could be attributed to repeated adherence counseling during each clinic follow-up visit and the use of alarm clocks daily for reminders on when the next ARV dose will be due

Anti-trypanosomal Activity of Potential Inhibitors of Trypanosoma brucei Glycolytic Pathway Enzymes Selected by Docking Studies

Human African trypanosomiasis (HAT); a potentially fatal protozoan infection caused by tsetse-fl mediated transmission of Trypanosoma brucei (T. Brucei); is largely recognized as a neglected disease. The repertoire of drugs that is effective against the infection is limited and all drugs have several drawbacks including high level of toxicity; difficult administration regimens; and the resurgence of resistance. At present the biology of the parasite is well studied and a number of technologies are now available which can aid in the identifiation of potential drug targets. This review identifis putative inhibitors of trypanosomal glycolytic enzymes

Genetic profile of Mycobacterium Tuberculosis and Treatment Outcomes in Human Pulmonary Tuberculosis in Tanzania

Information on the different spoligotype families of Mycobacterium tuberculosis in Tanzania is limited; and where available; restricted to small geographical areas. This article describes the genetic profile of M. tuberculosis across Tanzania and suggests how spoligotype families might affect drug resistance and treatment outcomes for smear positive pulmonary tuberculosis patients in Tanzania. We conducted the study from 2006 to 2008; and the isolates were obtained from samples collected under the routine drug resistance surveillance system. The isolates were from specimens collected from 2001 to 2007; and stored at the Central and Reference Tuberculosis Laboratory. A total of 487 isolates from 23 regions in the country were spoligotyped. We were able to retrieve clinical information for 446 isolates only. Out of the 487 isolates spoligotyped; 195(40.0) belonged to the Central Asian (CAS) family; 84 (17.5) to the Latin American Mediterranean (LAM) family; 49 (10.1) to the Latin American Mediterranean (LAM) family; 49 (10.1) to the East-African Indian (EAI) family; and 33 (6.8) to the Beijing family. Other isolates included 1 (0.2) for H37Rv; 10 (2.1) for Haarlem; 4 (0.8) for S family; 58 (11.9) for T family and 52 (10.7) for unclassified. No spoligotype patterns were consistent with M. bovis. Regarding treatment outcomes; the cure rate was 80 with no significant variation among the spoligotype families. The overall level of MDR TB was 2.5 (3/121); with no significant difference among the spoligotype families. All Beijing strains (11.8; 30/254) originated from the Eastern and Southern zones of the country; of which 80 were from Dar es Salaam. Isolates from the CAS and T families were reported disproportionately from the Eastern-Southern zone; and EAI and LAM families from the Northern-Lake zones but the difference was not statistically significant. Five isolates were identified as non-tuberculous Mycobacteria. In conclusion; M. tuberculosis isolates from pulmonary tuberculosis cases in Tanzania were classified mostly within the CAS; LAM; and EAI and T families; while the Beijing family comprised about 7 isolates only. Consistently good treatment outcomes were recorded across these spoligotype families. The proportion of drug resistance strains was low. The findings also suggest variation of spoligotype families with varying geographical localities within the country; and identify this area for further research to confirm this finding

Efficacy of Artemisinin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Nigerian Children

Introduction: The development and spread of Plasmodium falciparum resistance to most commonly used antimalarials remain a major challenge in the control of malaria. Constant monitoring of drug efficacy is an important tool in establishing rational antimalarial drug policies.Methodology: A randomized comparative study was conducted at the Wesley Guild Hospital; Ilesa; Nigeria between February 2010 and September 2011 comparing the efficacy and safety of artemether-lumefantrine (Coartem) and fixed dose of artesunate plus amodiaquine (Larimal) in the treatment of uncomplicated P. falciparum malaria in children betweem 6 and 144 months of age. P. falciparum malaria parasitemia was assessed by microscopy and rapid diagnostic test. Drugs were administered according to age for three days under supervision. The primary efficacy endpoint was a day 28 PCR-corrected parasitological cure. Results: A total of 182 patients were enrolled in the two treatment groups; Coartem (n = 101) and Larimal (n = 81); and tested after 28 days. In the intention-to-treat population; Coartem (n= 101) and Larimal (n= 81) had a PCR-corrected cure rate of 98 and 100 respectively; while in the per-protocol population; Coartem (n = 89) and Larimal (n = 71) both had a PCR-corrected cure rate of 100 at day 28. Although parasite and fever clearance time was faster in the Larimal group; no significant difference was observed between the two drugs. No serious adverse effects were reported. Conclusion: Five years after being introduced in Nigeria; both Coartem and Larimal have been shown to be safe and highly effective in the treatment of uncomplicated P. falciparum malaria in children

Importance of bacterial resistance in streptococcus pneumoniae and streptococcus pyogenes in the center region in Cameroon

Respiratory tract infections are a real public health problem; and the few studies of African data make difficult the definition of a probabilistic rational therapeutic approach. The present study from May 2006 to June 2007 included 107 strains of Streptococcus pneumoniae and 94 strains of Streptococcus pyogenes. A single isolate was collected by topic; and the minimum inhibitory concentration (MIC) has been made by the E test method; 201 strains from 115 adults and 86 children were included in the study. From 107 strains of S. pneumoniae; 24 were from children; and from 94 strains of S. pyogenes; 62 came from child. From antibiotics susceptibility of S. pyogenes; 100% were sensitive to penicillin G; with MIC between 0.064 and 0.128; 20 were resistant to erythromycin; and 100% were sensitive to levofloxacin; chloramphenicol; amoxicillin; cefotaxime; and ceftriaxone. From S. pneumoniae; 95.3% were sensitive to penicillin G and 4.7% were intermediate; 19.3% were resistant to erythromycin; 100% were sensitive to levofloxacin; cefotaxime amoxicillin; and ceftriaxone

Susceptibility to colistin of multi-resistant pseudomonas aeruginosa isolated in Douala Laquintinie Hospital, Cameroon

Pseudomonas aeruginosa is a germ of hospitalism responsible for nosocomial infections; it is naturally resistant to many antibiotics and has a high susceptibility to the acquisition of acquiring new resistance. The observation of strains highly resistant to antibiotics; has led us to look for possible alternative therapeutics. This study was a descriptive and cross-sectional one; conducted from October 2010 to March 2011. All patients hospitalized for at least 48 hours and showing sign of infection were included after obtaining their consent. Forty nine of 150 samples were positive to the cultivation of Pseudomonas aeruginosa showing a prevalence of 32.66%. For the antibiotic susceptibility; we obtain amikacin 57.14%; netilmicin 59.20%; ceftazidime 52.60%; imipenem 33%; colistin 97.95%; and ciprofloxacin 51%. Seven strains were resistant to all antibiotics tested other than colistin. One strain was resistant to colistin. Colistin retains high sensitivity to Pseudomonas aeruginosa. However; there are some strains multiresistant to antibiotics

Prevalence of Carbapenem Resistance Genes in Acinetobacter Baumannii Isolated From Clinical Specimens Obtained From an Academic Hospital in South Africa

Acinetobacter baumannii is an important cause of hospital-acquired infections. The occurrence of carbapenem resistance that is caused by the carbapenem-hydrolysing class D ?-lactamases and the metallo-?-lactamases (MBLs) limits the range of therapeutic alternatives in treating A. baumannii infections. In this study; two multiplex polymerase chain reactions were performed to screen for both carbapenem-hydrolysing class D ?-lactamases and MBL genes in 97 clinical isolates of A. baumannii. Oxacillinase (OXA)-51 had a prevalence of 83 (81/97); and OXA-23 had a prevalence of 59 (57/97). One isolate was positive for an MBL [Verona integron-encoded metallo ?-lactamases (VIM)]. Therefore; continuous surveillance and monitoring of A. baumannii is crucial because of the high prevalence of antibiotic resistance genes

Prevalence of Virulence Determinants in Staphylococcus Epidermidis from ICU Patients in Kampala; Uganda

Introduction: Staphylococcus epidermidis is often considered a non-pathogenic organism but it causes nosocomial infections. To distinguish invasive strains; comparative studies of patient and community isolates may offer some clues. We investigated the distribution of virulence determinants in patient isolates from Uganda. Methodology: S. epidermidis isolates were identified with the Staph API ID 32 kit. Antimicrobial susceptibility; biofilm formation and hemolysis were detected with standard procedures. Genes associated with virulence (aap; atlE; bhp; hla; hld; ica; IS256; sdrE; sea; tsst) and antimicrobial resistance (aac(6')-Ie-aph(2'')-Ia; aph(3')-IIIa; ant(4')-Ia; blaZ; mecA; vanA/vanB1) were detected by PCR. Results: S. epidermidis grew in 30 (30/50; 60) ICU samples and 20 (20/60; 33) community samples (one isolate per sample per patient/person). All ICU isolates (30/30; 100) were IS256 and hld positive; 22 (22/30; 73) were biofilm/ica positive; 21 (21/30; 70) were hemolytic on blood agar; nine (9/30; 30) contained atlE gene; six (6/30; 20) hla gene; five (5/30; 17) aap gene; and three (3/30; 10) bhp gene. A gene encoding an aminoglycoside-modifying enzyme; aph(3')-IIIa; was highly prevalent (28/30; 93); while blaZ (2/30; 7); mecA (3/30; 10); vanA (3/30; 10) and vanB1 (3/30; 10) were less prevalent. Of the community isolates; one (1/20; 5) was ica positive; two (2/20; 10) formed biofilms; and three (3/20; 15) possessed the atlE gene. bhp; aap; IS256; hld and antimicrobial resistance genes were not detected in community isolates. Conclusions: S. epidermidis from ICU patients in Mulago Hospital is potentially virulent and could be a reservoir for antimicrobial resistant genes

Childhood Urinary Tract Infection in Abakaliki: Etiological Organisms and Antibiotic Sensitivity Pattern

Urinary tract infection (UTI) is a common childhood infection in the Tropics which causes significant illness and is frequently missed; probably because of its non-specific presentation and similarity with other common illnesses. Objectives: To determine the prevalence; common etiological agents; and the susceptibility of these pathogens to the commonly available antimicrobial agents in this center. Materials and Methods: This was a retrospective study carried out at the Children's Outpatient Clinic and Children's Emergency Ward of Ebonyi State University Teaching Hospital Abakaliki (EBSUTH). The study was carried out between January 1; 2007 and December 31; 2009. Results: One hundred ten subjects of the 3625 children seen in the center during the period of study had UTI giving a case prevalence rate of 3.0. Majority of the patients (59; 53.6) were less than 2 years of age with a male:female ratio of 1:1.3. Fever was the commonest presenting symptom and the commonest organisms isolated in urine were Klebsiella (27; 24.5); and Staphylococcus aureus (24; 21.8). The drugs that were most sensitive to these organisms were Gentamicin (50; 45.5); Ceftriaxone (49; 44.5); and Ciprofloxacin (36; 32.7). Conclusion: The study revealed a high prevalence of UTI among children. Klebsiella was the commonest causative organism isolated in the urine. Gentamicin; Ceftriaxone; and Ciprofloxacin were the antimicrobials with the highest sensitivity to all the isolated microorganisms